Kopran Limited (NSE:KOPRAN)
India · Delayed Price · Currency is INR 164.00
-3.25 (-1.94%)
May 22, 2026, 3:29 PM IST
Kopran Revenue
In the fiscal year ending March 31, 2026, Kopran had annual revenue of 6.81B INR with 8.23% growth. Kopran had revenue of 2.34B in the quarter ending March 31, 2026, with 35.77% growth.
Revenue
6.81B
Revenue Growth
+8.23%
P/S Ratio
1.16
Revenue / Employee
6.66M
Employees
1,024
Market Cap
7.88B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.81B | 518.19M | 8.23% |
| Mar 31, 2025 | 6.30B | 150.13M | 2.44% |
| Mar 31, 2024 | 6.15B | 636.05M | 11.54% |
| Mar 31, 2023 | 5.51B | 734.66M | 15.38% |
| Mar 31, 2022 | 4.78B | -142.93M | -2.91% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 568.09B |
| Cipla | 277.12B |
| Apollo Hospitals Enterprise | 252.29B |
| Divi's Laboratories | 103.14B |
| Remus Pharmaceuticals | 8.60B |
| Sigachi Industries | 4.85B |
| GPT Healthcare | 4.78B |
| Tarsons Products | 4.14B |